Lupus & antiphospholipid syndrome
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups
Study context
- Population
- RCTs of pharmacological therapies for the initial management of lupus nephritis (LN), published 2000–2024124 arms in 61 RCTs
- Participants
- 7,058 participants
Methodological detailsdescriptive statistics, Fragility Index
- Descriptive statistics
- Fragility Index
Primary result
As reported in the abstract
Study design, included populations and outcome definitions of LN RCTs
- Arms with guideline-recommended therapies
- 79 (63.7%)
- MPAA arms
- 33 (26.6%)
- NIH-CYC arms
- 28 (22.6%)
- Triple-drug therapy arms
- 7 (5.6%)
- Triple-drug therapy RCTs multinational
- 100%
- NIH-CYC RCTs multinational
- 7.1%
- Tacrolimus RCTs multinational
- 0%
- RCTs with follow-up ≥24 months
- 9 (14.8%)
- RCTs exclusively including severe or refractory LN
- 10 (16.4%)
- RCTs reporting serious adverse events
- 29 (47.5%)
- Fragility Index (FI) of RCTs of double-drug guideline-recommended therapies (robustness mostly low)
- 1 to 3
Original publication
Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups. Lupus Sci Med. Published 20 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →